RT Journal Article
T1 Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain.
A1 Nolla, Joan M
A1 Rodríguez, Manuel
A1 Martin-Mola, Emilio
A1 Raya, Enrique
A1 Ibero, Isabel
A1 Nocea, Gonzalo
A1 Aragon, Belén
A1 Lizán, Luis
A1 Prades, Miriam
K1 Preferences
K1 Conjoint analysis
K1 Attributes
K1 Biological agents
K1 Rheumatic diseases
K1 Artritis psoriásica
K1 Artritis reumatoide
K1 Espondilitis anquilosante
K1 Factores biológicos
K1 Conducta de elección
K1 Estudios transversales
K1 Grupos focales
K1 Humanos
K1 Dolor
K1 Médicos
K1 Análisis de regresión
K1 Enfermedades reumáticas
K1 Grupos focales
K1 España
AB PURPOSETo define importance values assigned to attributes of biological agents (BAs) by Spanish patients with rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and rheumatologists.PATIENTS AND METHODSThis was an observational, cross-sectional design based upon a rank-based full-profile conjoint analysis. A literature review and four focus groups were undertaken to identify attributes and levels. An orthogonal matrix, combining the selected levels of attributes, was used to define scenarios. Participants ranked eight scenarios from 1 (most preferred) to 8 (least preferred). The relative importance (RI) of attributes was calculated. Multivariate regression analysis was performed to identify the characteristics that influenced the values of RI. A total of 488 patients (male 50.9%, mean age 50.6 [standard deviation {SD} 12.06] years, rheumatoid arthritis 33.8%, ankylosing spondylitis 32.4%, psoriatic arthritis 33.8%; mean time since diagnosis 12.6 [SD 8.2] years) and 136 rheumatologists (male 50.4%, mean age 46.4 [SD 9.1] years, mean time of practice 16.7 [SD 8.8] years) participated.RESULTSThe ideal BAs for patients and physicians, respectively, should allow pain relief and improvement of functional capacity (RI 39% and 44.7%), with low risk of adverse events (RI 24.9% and 30.5%), a long time prior to perceiving the need for a new dose (RI 16.4% and 12.4%), and self-administration at home (RI 19.7% and 12.5%), as identified through their preferences.CONCLUSIONAlthough efficacy and safety are paramount for patients and rheumatologists to make a choice regarding BAs, the need for a low frequency of administration and the administration method also play a role as preference attributes for BAs.
PB Dove Medical Press
SN 1177-889X (Online)
YR 2016
FD 2016-06-20
LK http://hdl.handle.net/10668/2527
UL http://hdl.handle.net/10668/2527
LA en
NO Nolla JM, Rodríguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, et al. Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence. 2016; 10:1101-13
NO Journal Article;
DS RISalud
RD Jul 5, 2025